Furthermore, relapsed neuroblastoma harbors an increased proportion of somatic mutations, with enrichment of ALK activating mutations compared to diagnostic tumors, with a frequency of 20% and rising as we sequence patient tumors and/or plasma more routinely at the time of relapse6–9. The gene discussed is ALK; the disease is neuroblastoma.